Login / Signup

Pharmacokinetics and safety of twice-daily ritonavir-boosted atazanavir with rifampicin.

Kamunkhwala GausiHenry MugerwaMarco SiccardiMaiara Camotti MontanhaMohammed LamordeLubbe WiesnerAntonio D'AvolioHelen McIlleronEd WilkinsAmedeo De NicolòGary MaartensSaye KhooCissy KityoPaolo DentiCatriona Waitt
Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
Twice daily atazanavir/ritonavir during rifampicin co-administration was well-tolerated and achieved plasma concentrations above the target.
Keyphrases
  • mycobacterium tuberculosis
  • hiv infected patients
  • antiretroviral therapy
  • pulmonary tuberculosis
  • physical activity